# BioNTech to Evaluate Pumitamig With Gilead’s Trodelvy

By John Kim

Canonical URL: https://www.tokenpost.com/news/business/39062
Published: 2026-10-23T14:47:29.000Z
Updated: 2026-10-23T14:47:29.000Z
Section: Business

> The companies are examining the combination as an initial treatment for triple-negative breast cancer with low or absent PD-L1 expression.

BioNTech will evaluate pumitamig alongside Gilead Sciences’ Trodelvy as an initial treatment option for patients with triple-negative breast cancer and low or absent PD-L1 expression. BioNTech announced the collaboration Thursday.